PHILADELPHIA, Oct. 06, 2015 (GLOBE NEWSWIRE) -- Brainsway (TASE:BRIN), the leader in the development of advanced noninvasive treatments for brain disorders, today announced its partnership with the United States Navy to implement Deep Transcranial Magnetic Stimulation (Deep TMS). The devices purchased by the Navy will be used to help treat sailors suffering from clinical depression, with the first system to be deployed in San Diego, California.

“The Navy’s purchase of our Deep TMS devices is indicative of its ongoing efforts to bring the most advanced medical treatments to the men and women who serve our country,” said Dr. Guy Ezekiel, chief executive officer of Brainsway. “It is our honor to partner with the Navy in its commitment to ensuring the mental health and safety of U.S. sailors.”  

Brainsway’s Deep TMS system is used to treat depression in patients who have previously been unable to manage their disorder with antidepressants. For military members and their families receiving medical treatment on base, this can bring hope to those facing a very real crisis. Due to the high pressure and anxiety of serving in a military role, rates of depression and suicide are higher among service members and their families – 22 veterans commit suicide every day.1 Brainsway can help relieve depressive symptoms for many of these individuals.

Deep TMS is a noninvasive therapy that uses Brainsway’s patented design to generate brief magnetic fields at an amplitude similar to those used in magnetic resonance imaging (MRI). Patients sit beneath a helmet that transmits the magnetic fields and directs them into the brain region where depressive symptoms originate. The therapy has been used to treat more than 6,000 patients and in more than 70 U.S. clinics, in some of the leading institutions in the world.

About Brainsway

Brainsway Ltd. is dedicated to the development and marketing of the Deep TMS (Transcranial Magnetic Stimulation) technology for the treatment of brain disorders. Brainsway’s unique therapy is based on patents filed by the National Institutes of Health (NIH) and by the company. Brainsway holds the exclusive license from the NIH for the patent and technology. Brainsway's Deep TMS therapy has been cleared by the FDA for treatment of depression patients who do not respond to any number of medication treatments in the current depressive episode. The treatment has been enthusiastically received by the international academic community, with 60 clinical trials conducted in major institutions worldwide. For more information, please visit

1 Department of Veterans Affairs, 2012


Media Contact:
Brigit Carlson